Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy  

作　　者：Gianluca Santamaria Mario Cioce Antonia Rizzuto Vito Michele Fazio Giuseppe Viglietto Maria Lucibello 

机构地区：[1]Department of Experimental and Clinical Medicine,“Magna Graecia”University of Catanzaro,Catanzaro 88100,Italy [2]Department of Medicine,Laboratory of Molecular Medicine and Biotechnology,University Campus Bio-Medico of Rome,Rome 00128,Italy [3]Institute of Translational Pharmacology,National Research Council of Italy(CNR),Rome 00133,Italy [4]Department of Medical and Surgical Sciences,“Magna Graecia”University of Catanzaro,Catanzaro 88100,Italy [5]Department of Biomedical Sciences,Institute for Biomedical Research and Innovation,National Research Council of Italy(CNR),Catanzaro 88100,Italy

出　　处：《Cancer Drug Resistance》2023年第3期447-467,共21页癌症耐药（英文）

摘　　要：Early identification of breast cancer (BC) patients at a high risk of progression may aid in therapeutic and prognostic aims. This is especially true for metastatic disease, which is responsible for most cancer-related deaths. Growing evidence indicates that the translationally controlled tumor protein (TCTP) may be a clinically relevant marker for identifying poorly differentiated aggressive BC tumors. TCTP is an intriguing protein with pleiotropic functions, which is involved in multiple signaling pathways. TCTP may also be involved in stress response, cell growth and proliferation-related processes, underlying its potential role in the initiation of metastatic growth. Thus, TCTP marks specific cancer cell sub-populations with pronounced stress adaptation, stem-like and immune-evasive properties. Therefore, we have shown that in vivo phospho-TCTP levels correlate with the response of BC cells to anti-HER2 agents. In this review, we discuss the clinical relevance of TCTP for personalized therapy, specific TCTP-targeting strategies, and currently available therapeutic agents. We propose TCTP as an actionable clinically relevant target that could potentially improve patient outcomes.

关 键 词：Breast cancer METASTASIS TCTP stem cells therapy resistance BIOMARKER 

分 类 号：R737.9[医药卫生—肿瘤]